| scholarly article | Q13442814 |
| P2093 | author name string | Harris LA | |
| Xie D | |||
| Fox JA | |||
| Totpal K | |||
| Kelley SK | |||
| Deforge L | |||
| Bussiere J | |||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | apoptotic process | Q14599311 |
| pharmacokinetics | Q323936 | ||
| P304 | page(s) | 31-38 | |
| P577 | publication date | 2001-10-01 | |
| P1433 | published in | Journal of Pharmacology and Experimental Therapeutics | Q1500272 |
| P1476 | title | Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety | |
| P478 | volume | 299 |
| Q35200982 | A cell-based high-throughput screen to identify synergistic TRAIL sensitizers |
| Q35303638 | A humanized leucine zipper-TRAIL hybrid induces apoptosis of tumors both in vitro and in vivo |
| Q38307538 | A mechanism of resistance to TRAIL/Apo2L-induced apoptosis of newly established glioma cell line and sensitisation to TRAIL by genotoxic agents |
| Q33907576 | A novel cationic lipid with intrinsic antitumor activity to facilitate gene therapy of TRAIL DNA. |
| Q39744489 | A novel molecule integrating therapeutic and diagnostic activities reveals multiple aspects of stem cell-based therapy. |
| Q34384021 | Advances in Viral Vector-Based TRAIL Gene Therapy for Cancer |
| Q51662524 | An intermittent approach for cancer chemoprevention. |
| Q37405568 | Annexin V-TRAIL fusion protein is a more sensitive and potent apoptotic inducer for cancer therapy |
| Q35653261 | Antiangiogenic variant of TSP-1 targets tumor cells in glioblastomas |
| Q39659194 | Anticancer efficacy of Apo2L/TRAIL is retained in the presence of high and biologically active concentrations of osteoprotegerin in vivo. |
| Q37412514 | Antitherapeutic antibody-mediated hepatotoxicity of recombinant human Apo2L/TRAIL in the cynomolgus monkey |
| Q33658976 | Antitumor Activity of a Mesenchymal Stem Cell Line Stably Secreting a Tumor-Targeted TNF-Related Apoptosis-Inducing Ligand Fusion Protein |
| Q39874761 | Apo2L/TRAIL inhibits tumor growth and bone destruction in a murine model of multiple myeloma |
| Q39790634 | Apomab, a fully human agonistic antibody to DR5, exhibits potent antitumor activity against primary and metastatic breast cancer |
| Q33753135 | Bi-specific molecule against EGFR and death receptors simultaneously targets proliferation and death pathways in tumors |
| Q31172628 | Calculation of a First-In-Man Dose of 7-O-Succinyl Macrolactin A Based on Allometric Scaling of Data from Mice, Rats, and Dogs |
| Q36936884 | Carbenoxolone enhances TRAIL-induced apoptosis through the upregulation of death receptor 5 and inhibition of gap junction intercellular communication in human glioma. |
| Q35186676 | Cellular FLICE-inhibitory protein: an attractive therapeutic target? |
| Q43172447 | Ceramide synthase 6 modulates TRAIL sensitivity and nuclear translocation of active caspase-3 in colon cancer cells. |
| Q35094229 | Chemotherapeutic approaches for targeting cell death pathways |
| Q37073330 | Colony-Stimulating Factor 1 Receptor Antagonists Sensitize Human Immunodeficiency Virus Type 1-Infected Macrophages to TRAIL-Mediated Killing |
| Q35972500 | Combination of TRAIL and actinomycin D liposomes enhances antitumor effect in non-small cell lung cancer |
| Q35919697 | Combinatorial chemotherapeutic efficacy in non-Hodgkin lymphoma can be predicted by a signaling model of CD20 pharmacodynamics |
| Q37832083 | Combined modality therapy with TRAIL or agonistic death receptor antibodies. |
| Q37761322 | Combining naturally occurring polyphenols with TNF-related apoptosis-inducing ligand: a promising approach to kill resistant cancer cells? |
| Q36395984 | Delivery of tumor-homing TRAIL sensitizer with long-acting TRAIL as a therapy for TRAIL-resistant tumors |
| Q35543789 | Detection of Anticancer and Apoptotic Effect of the Produced IgYs against the Three Extracellular Domain of Human DR5 Protein |
| Q39455419 | Development of a radioiodinated apoptosis-inducing ligand, rhTRAIL, and a radiolabelled agonist TRAIL receptor antibody for clinical imaging studies |
| Q33999606 | Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. |
| Q24793079 | Doxorubicin increases the effectiveness of Apo2L/TRAIL for tumor growth inhibition of prostate cancer xenografts |
| Q34257806 | Effect of hyperthermia in combination with TRAIL on the JNK-Bim signal transduction pathway and growth of xenograft tumors |
| Q37482834 | Engineered adenovirus fiber shaft fusion homotrimer of soluble TRAIL with enhanced stability and antitumor activity |
| Q33689870 | Engineering a leucine zipper-TRAIL homotrimer with improved cytotoxicity in tumor cells |
| Q35590091 | Enhancing the antitumor efficacy of a cell-surface death ligand by covalent membrane display. |
| Q35653933 | Evaluation of pharmacodynamic biomarkers in a Phase 1a trial of dulanermin (rhApo2L/TRAIL) in patients with advanced tumours |
| Q39325378 | Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy |
| Q90733230 | Genetically Modified DR5-Specific TRAIL Variant DR5-B Revealed Dual Antitumor and Protumoral Effect in Colon Cancer Xenografts and an Improved Pharmacokinetic Profile |
| Q37416883 | Genetically engineered donor T cells to optimize graft-versus-tumor effects across MHC barriers |
| Q37302038 | Guiding TRAIL to cancer cells through Kv10.1 potassium channel overcomes resistance to doxorubicin. |
| Q24650617 | HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo |
| Q36134152 | Hetero-modification of TRAIL trimer for improved drug delivery and in vivo antitumor activities |
| Q38806320 | Human umbilical cord mesenchymal stem cells delivering sTRAIL home to lung cancer mediated by MCP-1/CCR2 axis and exhibit antitumor effects |
| Q36777316 | Improved antitumor activity and tumor targeting of NH(2)-terminal-specific PEGylated tumor necrosis factor-related apoptosis-inducing ligand |
| Q37657813 | Improved antitumor activity of TRAIL fusion protein via formation of self-assembling nanoparticle |
| Q41483641 | Improvement of Pharmacokinetic Profile of TRAIL via Trimer-Tag Enhances its Antitumor Activity in vivo |
| Q59224646 | In vivo anti-lymphoma activity of an agonistic human recombinant anti-TRAIL-R2 minibody |
| Q34803686 | In vivo gene delivery by embryonic-stem-cell-derived astrocytes for malignant gliomas |
| Q36366424 | Intracellular-signaling tumor-regression modeling of the pro-apoptotic receptor agonists dulanermin and conatumumab |
| Q35863285 | Kinetics in signal transduction pathways involving promiscuous oligomerizing receptors can be determined by receptor specificity: apoptosis induction by TRAIL. |
| Q64255100 | MEDI3039, a novel highly potent tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 agonist, causes regression of orthotopic tumors and inhibits outgrowth of metastatic triple-negative breast cancer |
| Q38697040 | ML327 induces apoptosis and sensitizes Ewing sarcoma cells to TNF-related apoptosis-inducing ligand |
| Q38115574 | Manipulating the apoptotic pathway: potential therapeutics for cancer patients |
| Q57174410 | Mesenchymal Stem Cell Expressing TRAIL as Targeted Therapy against Sensitised Tumour |
| Q39297108 | Mitomycin C potentiates TRAIL-induced apoptosis through p53-independent upregulation of death receptors: evidence for the role of c-Jun N-terminal kinase activation. |
| Q37517140 | Mix to validate: a facile, reversible PEGylation for fast screening of potential therapeutic proteins in vivo |
| Q33805582 | Modulation of TRAIL resistance in colon carcinoma cells: different contributions of DR4 and DR5. |
| Q91716512 | Molecular Mode of Action of TRAIL Receptor Agonists-Common Principles and Their Translational Exploitation |
| Q34135640 | Multi-layered nanoparticles for combination gene and drug delivery to tumors. |
| Q38931192 | Multivalent nanobodies targeting death receptor 5 elicit superior tumor cell killing through efficient caspase induction |
| Q37473651 | Nanoparticle engineered TRAIL-overexpressing adipose-derived stem cells target and eradicate glioblastoma via intracranial delivery |
| Q47707153 | Nanoparticles for Immune Cytokine TRAIL-Based Cancer Therapy. |
| Q36608654 | Newly established tumourigenic primary human colon cancer cell lines are sensitive to TRAIL-induced apoptosis in vitro and in vivo |
| Q35371213 | Noninvasive imaging of therapeutic gene expression using a bidirectional transcriptional amplification strategy |
| Q39528587 | Off-target lapatinib activity sensitizes colon cancer cells through TRAIL death receptor up-regulation |
| Q37586895 | Oncolytic adenovirus encoding tumor necrosis factor-related apoptosis inducing ligand (TRAIL) inhibits the growth and metastasis of triple-negative breast cancer |
| Q26768160 | Onto better TRAILs for cancer treatment |
| Q42278494 | Overexpression of Bcl2 abrogates chemo- and radiotherapy-induced sensitisation of NCI-H460 non-small-cell lung cancer cells to adenovirus-mediated expression of full-length TRAIL. |
| Q36777280 | PEG-transferrin conjugated TRAIL (TNF-related apoptosis-inducing ligand) for therapeutic tumor targeting |
| Q53451676 | PEGylated TNF-related apoptosis-inducing ligand (TRAIL)-loaded sustained release PLGA microspheres for enhanced stability and antitumor activity |
| Q35570425 | Parallel screening of FDA-approved antineoplastic drugs for identifying sensitizers of TRAIL-induced apoptosis in cancer cells |
| Q44230417 | Pegylated TRAIL retains anti-leukemic cytotoxicity and exhibits improved signal transduction activity with respect to TRAIL. |
| Q37719266 | Polymeric mechanical amplifiers of immune cytokine-mediated apoptosis |
| Q35579375 | Potent and tumor specific: arming bacteria with therapeutic proteins |
| Q34546374 | Potent antitumoral activity of TRAIL through generation of tumor-targeted single-chain fusion proteins. |
| Q34134426 | Potent, tumor-specific gene expression in an orthotopic hepatoma rat model using a Survivin-targeted, amplifiable adenoviral vector |
| Q37585453 | Potential application of temozolomide in mesenchymal stem cell-based TRAIL gene therapy against malignant glioma |
| Q39673935 | Preparation and Characterization of Apo2L/TNF-Related Apoptosis-Inducing Ligand–Loaded Human Serum Albumin Nanoparticles with Improved Stability and Tumor Distribution |
| Q26796270 | Principles of antibody-mediated TNF receptor activation |
| Q45148594 | Production of functional native human interleukin-2 in tobacco chloroplasts |
| Q35183874 | Recombinant human CD19L-sTRAIL effectively targets B cell precursor acute lymphoblastic leukemia |
| Q46326788 | Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid tumors |
| Q37075273 | Secretory TRAIL-Armed Natural Killer Cell-Based Therapy: In Vitro and In Vivo Colorectal Peritoneal Carcinomatosis Xenograft |
| Q53700386 | Sensitization of recombinant human tumor necrosis factor-related apoptosis-inducing ligand-resistant malignant melanomas by quercetin. |
| Q61797115 | Soluble TRAIL Armed Human MSC As Gene Therapy For Pancreatic Cancer |
| Q35555592 | Soluble TRAIL concentrations are raised in patients with systemic lupus erythematosus. |
| Q37024785 | Structural insights of homotypic interaction domains in the ligand-receptor signal transduction of tumor necrosis factor (TNF). |
| Q37029804 | Systemic PEGylated TRAIL treatment ameliorates liver cirrhosis in rats by eliminating activated hepatic stellate cells |
| Q37440765 | TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies |
| Q34291312 | TRAIL in cancer therapy: present and future challenges |
| Q37016549 | TRAIL induces apoptosis in oral squamous carcinoma cells--a crosstalk with oncogenic Ras regulated cell surface expression of death receptor 5. |
| Q37433463 | TRAIL on trial: preclinical advances in cancer therapy |
| Q35770748 | TRAIL protein expression in breast cancer cells correlates with nuclear grade |
| Q37972139 | TRAIL receptor signaling and therapeutic option in bone tumors: the trap of the bone microenvironment. |
| Q60960591 | TRAIL stabilization and cancer cell sensitization to its pro-apoptotic activity achieved through genetic fusion with arginine deiminase |
| Q34383454 | TRAIL treatment provokes mutations in surviving cells |
| Q28548386 | TRAIL-Based High Throughput Screening Reveals a Link between TRAIL-Mediated Apoptosis and Glutathione Reductase, a Key Component of Oxidative Stress Response |
| Q50054799 | TRAIL-Induced Apoptosis in TRAIL-Resistant Breast Carcinoma Through Quercetin Cotreatment. |
| Q35239558 | TRAIL-induced apoptosis is enhanced by heat shock protein 70 expression |
| Q37889112 | TRAIL-mediated signaling in prostate, bladder and renal cancer |
| Q37012681 | TRAIL-receptor 1 IgM antibodies strongly induce apoptosis in human cancer cells in vitro and in vivo |
| Q39056037 | Targeted induction of apoptosis in glioblastoma multiforme cells by an MRP3-specific TRAIL fusion protein in vitro |
| Q37602717 | Targeting cell death signaling in colorectal cancer: current strategies and future perspectives |
| Q37356520 | Targeting multiple pathways in gliomas with stem cell and viral delivered S-TRAIL and Temozolomide |
| Q92987959 | Targeting of CD133+ Cancer Stem Cells by Mesenchymal Stem Cell Expressing TRAIL Reveals a Prospective Role of Apoptotic Gene Regulation in Non-Small Cell Lung Cancer |
| Q38120535 | Targeting of the tumor necrosis factor receptor superfamily for cancer immunotherapy |
| Q35172090 | The Biology of TRAIL and the Role of TRAIL-Based Therapeutics in Infectious Diseases |
| Q36511919 | The TRAIL to targeted therapy of breast cancer |
| Q36312145 | The inhibitory effect of MSCs expressing TRAIL as a cellular delivery vehicle in combination with cisplatin on hepatocellular carcinoma |
| Q36792997 | The promise of TRAIL--potential and risks of a novel anticancer therapy |
| Q36733723 | The role of the mitochondria in mediating cytotoxicity of anti-cancer therapies |
| Q36742314 | The synergistic apoptotic interaction of Indole-3-Carbinol and Genistein with TRAIL on endometrial cancer cells |
| Q90616999 | Trimer form of tumor necrosis factor-related apoptosis inducing ligand induces apoptosis in canine cell lines derived from mammary tumors |
| Q36836285 | Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) Promotes Angiogenesis and Ischemia-Induced Neovascularization Via NADPH Oxidase 4 (NOX4) and Nitric Oxide-Dependent Mechanisms |
| Q38554434 | Tumor cell-selective apoptosis induction through targeting of K(V)10.1 via bifunctional TRAIL antibody. |
| Q36218165 | Tumor priming by Apo2L/TRAIL reduces interstitial fluid pressure and enhances efficacy of liposomal gemcitabine in a patient derived xenograft tumor model |
| Q33809123 | Tumor-targeted delivery of biologically active TRAIL protein. |
| Q38998166 | Tumour-associated mesenchymal stem/stromal cells: emerging therapeutic targets. |
| Q37424066 | Tumour-targeted delivery of TRAIL using Salmonella typhimurium enhances breast cancer survival in mice. |
| Q58599910 | Tumour-targeting bacteria engineered to fight cancer |
| Q35082212 | Valproic acid, an antiepileptic drug with histone deacetylase inhibitory activity, potentiates the cytotoxic effect of Apo2L/TRAIL on cultured thoracic cancer cells through mitochondria-dependent caspase activation |
Search more.